Skip to main content
. Author manuscript; available in PMC: 2022 Dec 13.
Published in final edited form as: Clin Cancer Res. 2022 Jun 13;28(12):2646–2656. doi: 10.1158/1078-0432.CCR-21-0645

Figure 5. Changes in Cytokines:

Figure 5.

Nine participants had serial plasma samples available for cytokine measurement. In participants with high baseline levels of the pro-inflammatory cytokines IL1b, IL6 or IL8, these cytokines trended down rapidly after initiation of lenalidomide. By contrast, IL10, an anti-inflammatory cytokine, and IL12, a TH1-promoting immune stimulatory cytokine, trended up.